Lineage Cell Therapeutics (LCTX) Net Cash Flow (2010 - 2026)

Lineage Cell Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$4.8 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 334.98% year-over-year to -$4.8 million in Q1 2026; TTM through Mar 2026 was -$12.3 million, a 385.55% decrease from a year earlier, with the FY2025 full-year figure at -$5.4 million, down 151.89% from the prior year.
• Net Cash Flow slipped to -$4.8 million in Q1 2026 per LCTX's latest filing, from $167000.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $22.4 million in Q1 2022 and bottomed at -$45.4 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$1.8 million (2025), against an average of -$1.1 million.
• Across the five-year window, Net Cash Flow tumbled 3695.32% in 2022 and jumped 385.8% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$13.3 million in 2022, then jumped by 127.93% to $3.7 million in 2023, then soared by 385.8% to $18.0 million in 2024, then sank by 99.07% to $167000.0 in 2025, then plunged by 3000.0% to -$4.8 million in 2026.
• Per Business Quant, the three latest LCTX Net Cash Flow figures stand at -$4.8 million (Q1 2026), $167000.0 (Q4 2025), and -$1.8 million (Q3 2025).